Common use of Reversion Rights Clause in Contracts

Reversion Rights. If AstraZeneca decides not to file, prosecute or maintain any Patent Right under Section 8.4.1 or 8.4.3, it shall give ▇▇▇▇▇▇▇▇▇ reasonable notice to that effect sufficiently in advance of any deadline for any filing with respect to such Patent Right so as to permit ▇▇▇▇▇▇▇▇▇ to carry out such activity. Upon delivery of such notice, ▇▇▇▇▇▇▇▇▇ shall have the right to file, prosecute and maintain such Patent Right, and AstraZeneca shall perform such acts as may be reasonably necessary for ▇▇▇▇▇▇▇▇▇ to file, prosecute or maintain such Patent Right, at ▇▇▇▇▇▇▇▇▇’▇ sole cost and expense. If ▇▇▇▇▇▇▇▇▇ does so elect, then AstraZeneca shall provide such cooperation to ▇▇▇▇▇▇▇▇▇, including the execution and filing of appropriate instruments, as may reasonably be requested to facilitate the transition of such patent activities, and shall assign all of its right, title and interest to such Patent Right to ▇▇▇▇▇▇▇▇▇. Any such Patent Right abandoned by AstraZeneca under Section 8.4.1 or 8.4.3 shall be deemed to be excluded from the ▇▇▇▇▇▇▇▇▇ Patent Rights or Joint Patent Rights, as applicable, and shall thereafter cease to be included within the scope of the licenses granted to AstraZeneca under Section 2.

Reversion Rights. If AstraZeneca decides not to file, prosecute or maintain any Patent Right under Section 8.4.1 or 8.4.3, it shall give ▇▇▇▇▇▇▇▇▇ reasonable notice to that effect sufficiently in advance of any deadline for any filing with respect to such Patent Right so as to permit ▇▇▇▇▇▇▇▇▇ to carry out such activity. Upon delivery of such notice, ▇▇▇▇▇▇▇▇▇ shall have the right to file, prosecute and maintain such Patent Right, and AstraZeneca shall perform such acts as may be reasonably necessary for ▇▇▇▇▇▇▇▇▇ to file, prosecute or maintain such Patent Right, at ▇▇▇▇▇▇▇▇▇’▇ sole cost and expense. If ▇▇▇▇▇▇▇▇▇ does so elect, then AstraZeneca shall [**] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. provide such cooperation to ▇▇▇▇▇▇▇▇▇, including the execution and filing of appropriate instruments, as may reasonably be requested to facilitate the transition of such patent activities, and shall assign all of its right, title and interest to such Patent Right to ▇▇▇▇▇▇▇▇▇. Any such Patent Right abandoned by AstraZeneca under Section 8.4.1 or 8.4.3 shall be deemed to be excluded from the ▇▇▇▇▇▇▇▇▇ Patent Rights or Joint Patent Rights, as applicable, and shall thereafter cease to be included within the scope of the licenses granted to AstraZeneca under Section 2.